首页> 外文期刊>Nature >IgG1 protects against renal disease in a mouse model of cryoglobulinaemia
【24h】

IgG1 protects against renal disease in a mouse model of cryoglobulinaemia

机译:IgG1在小鼠冰球蛋白血症模型中预防肾脏疾病

获取原文
获取原文并翻译 | 示例
       

摘要

Immunoglobulins protect against disease to a considerable extent by activating complement and stimulatory immunoglobulin crystallizable fragment receptors (Ig FcRs), and aggregating microbial pathogens. Yet IgG1, the predominant murine serum Ig isotype, cannot activate complement by the classical pathway, binds more avidly to an inhibitory than to stimulatory FcRs, and has limited ability to aggregate pathogens. In these regards, it resembles human IgG4 (ref. 4). We hypothesized that limited ability to activate effector mechanisms might protect against immune complex immunopathology. Here we show that IgG1-deficient (γ1~-) mice, immunized with a potent antigen, develop lethal renal disease soon after they begin to produce antigen-specific antibody, whereas similarly immunized wild-type mice remain healthy. Surprisingly, renal disease in this model is complement and FcR independent and results from immune complex precipitation in glomerular capillaries, as in some cryoglobu-linaemic humans. IgG3, which self-associates to form large immune complexes, accounts for more than 97% of the mouse Ig in this cryoglobulin; furthermore, glomerular disease develops when mice are injected with IgG3 anti-trinitrophenyl (TNP) monoclonal antibody followed by a TNP-labelled protein. Renal disease is prevented in both active and passive immunization models by antigen-specific IgG1; other isotypes are less potent at preventing disease. These observations demonstrate the adaptive significance of Ig isotypes that poorly activate effector mechanisms, reveal an immune-complex-dependent, complement- and FcR-independent nephrotoxic mechanism, and suggest that isotypes that poorly activate effector mechanisms may be useful for inhibiting immune complex immunopathology.%一些免疫球蛋白异形体(如小鼠IgG1和人类IgG4)几乎没有能力诱导效应子机制: 它们不能高效活化、补足、刺激免疫球蛋白可结晶片段受体(FcRs)或聚集抗原。那么它们干什么呢? Richard Strait等人提供的证据表明,IgG1(占主导地位的小鼠IgG子类)有调控功能,通过与IgG3竞争抗原和提高免疫复合物可溶性来防止由IgG3免疫复合物驱动的肾病的发生。这一结果表明,在活化效应子机制方面性能差的IgG异形体也许能通过其他手段防止由免疫复合物造成的免疫疾病。
机译:免疫球蛋白可以通过激活补体和刺激性免疫球蛋白可结晶片段受体(Ig FcRs)并聚集微生物病原体,在很大程度上预防疾病。然而,主要的鼠血清Ig同种型IgG1无法通过经典途径激活补体,与抑制性抗体的结合要比与刺激性FcR的结合更紧密,并且聚集病原体的能力有限。在这些方面,它类似于人IgG4(参考文献4)。我们假设激活效应子机制的能力有限可能会防御免疫复合物免疫病理学。在这里,我们显示了用强力抗原免疫的IgG1缺失(γ1〜-)小鼠在开始产生抗原特异性抗体后不久就发生了致命的肾脏疾病,而同样免疫的野生型小鼠仍然健康。出人意料的是,在该模型中,肾脏疾病是补体和FcR独立性,是由肾小球毛细血管中免疫复合物的沉淀所致,如某些冷冻球蛋白血症人。自缔形成大型免疫复合物的IgG3占该球蛋白中小鼠Ig的97%以上;此外,当给小鼠注射IgG3抗三硝基苯基(TNP)单克隆抗体,然后注射TNP标记的蛋白时,就会出现肾小球疾病。抗原特异性IgG1可在主动和被动免疫模型中预防肾脏疾病。其他同种型在预防疾病方面作用较小。这些观察结果表明,Ig亚型的适应性意义很弱,无法激活效应器机制,揭示了免疫复合物依赖性,补体和FcR独立的肾毒性机制,并且表明,低效激活效应器机制的同种型可能对抑制免疫复合物免疫病理学有用。 %一些免疫球蛋白异形体(如小鼠IgG1和人类IgG4)几乎没有能力诱导效应子机制:它们不能高效活化,补足,刺激免疫球蛋白可结晶片段受体(FcRs)或聚集抗原。那么它们干什么呢?Richard Strait等人提供的证据证明,IgG1(占主导地位的小鼠IgG子类)有转变功能,通过与IgG3竞争抗原和提高免疫复合物可溶性来防止由IgG3免疫复合物驱动的肾病的发生。结果表明,在活化效应子机制方面性能差异的IgG异形体也许能通过其他手段防止由免疫复合物造成的免疫疾病。

著录项

  • 来源
    《Nature》 |2015年第7535期|501-504a2|共5页
  • 作者单位

    Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA,Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA;

    Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA;

    Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA;

    Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA;

    Department of Medicine, University of Southern California School of Medicine, Los Angeles, California 90033, USA;

    Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA,Institute for Systemic Inflammation Research, University of Luebeck, 23538 Luebeck, Germany;

    Institute for Systemic Inflammation Research, University of Luebeck, 23538 Luebeck, Germany;

    Division of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA;

    Division of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA;

    Division of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA;

    Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA;

    Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA;

    Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA,Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA;

    Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA,Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA,Medical Service, Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio 45220, USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:52:26

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号